Sandoz, the generic pharmaceuticals division of the Novartis Group, is a global leader in the rapidly growing generics industry.
Sandoz is committed to increasing global access to affordable healthcare by developing, manufacturing and commercializing a broad portfolio of high-quality medicines following loss of patent protection. Sandoz specializes in differentiated, added-value products, which already comprise well over one third (by sales) of its portfolio of approximately 1000 compounds. These differentiated products predominantly focus on the biosimilar, oncology injectable and respiratory fields, while other key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies.
Sandoz benefits from a comprehensive global development and production network as well as a commercial presence in more than 130 countries. Its wide range of products covers all stages of the development and production processes, from basic molecules to finished medicines, and is available to approximately 90% of the world’s population. This combination of specialist expertise and extensive global presence gives Sandoz a competitive advantage that has positioned it as one of the two top players in the global generics industry. In 2009, Sandoz employed around 23,000 people worldwide and posted sales of USD 7.5 billion.